Cerevel licenses several CNS assets from Pfizer concurrent with spin-off as independent company
Concurrent with being spun-off from Pfizer Inc. and Bain Capital, Boston-based Cerevel Therapeutics LLC has in-licensed several neuroscience assets from the Big Pharma.
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com